Paper Details

  1. Home
  2. Paper Details

Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease.

Author: WatersC

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

COMT inhibitors, such as tolcapone, are used in conjunction with levodopa to improve the duration of action of levodopa in Parkinson's disease. While they can augment dopaminergic effects and require levodopa dose adjustment, monitoring for liver function abnormalities is crucial.
Paper Details　
Original Abstract of the Article :
Catechol-O-methyltransferase (COMT) inhibitors are a new therapeutic option in the treatment of patients with Parkinson's disease. COMT inhibitors act by extending the duration of action of levodopa, thus improving the amount of time a patient can experience benefit from levodopa. COMT inhibitors ar...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1532-5415.2000.tb04732.x

データ提供：米国国立医学図書館（NLM）

Parkinson's Disease: Catechol-O-methyltransferase (COMT) Inhibitors

In the vast and challenging world of [neurology], researchers are constantly seeking ways to improve the lives of patients suffering from [Parkinson's disease]. This study explores the potential of [catechol-O-methyltransferase (COMT) inhibitors] in managing the symptoms of Parkinson's disease. The researchers examine the role of these inhibitors in extending the duration of action of [levodopa], a key medication for Parkinson's disease, and improving patient well-being. Their findings offer valuable insights into the potential of COMT inhibitors as a valuable addition to the therapeutic arsenal for managing Parkinson's disease.

Extending Levodopa's Reach: The Role of COMT Inhibitors

This study investigates the potential of [catechol-O-methyltransferase (COMT) inhibitors] in managing [Parkinson's disease]. The researchers found that COMT inhibitors can effectively extend the duration of action of [levodopa], a key medication for Parkinson's disease, leading to improved symptom control and overall well-being. This is like finding a new and efficient caravan route through the desert, allowing for a longer and more comfortable journey. The study highlights the potential of COMT inhibitors as a valuable addition to the therapeutic arsenal for managing Parkinson's disease, offering hope for patients seeking a more effective and personalized approach to their treatment.

Navigating the Desert of Parkinson's Disease: A New Approach

This study explores the potential of [catechol-O-methyltransferase (COMT) inhibitors] in managing the symptoms of [Parkinson's disease]. It's like discovering a hidden oasis in the heart of the desert, offering a source of relief and a new path forward for patients battling this challenging condition. The research suggests that COMT inhibitors can effectively extend the duration of action of levodopa, a key medication for Parkinson's disease, potentially leading to improved symptom control and a better quality of life.

Dr.Camel's Conclusion

This research highlights the potential of [catechol-O-methyltransferase (COMT) inhibitors] as a valuable tool in the management of [Parkinson's disease]. It's a reminder that just as a desert traveler seeks a reliable source of water to sustain their journey, we must continue to explore new and innovative therapies that can improve the lives of patients with Parkinson's disease.

Date :
  1. Date Completed 2000-06-28
  2. Date Revised 2019-07-09
Further Info :

Pubmed ID

10855610

DOI: Digital Object Identifier

10.1111/j.1532-5415.2000.tb04732.x

Related Literature

Article Analysis
・Side Effects of tolcapone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.